Latent Hit Identification in Primary Screening Data with Compound Set Enrichment
Thibault Varin, PostDoctoral Fellow, Novartis, Speaking at Medchem Europe 2011.
Date Posted: Thursday, December 01, 2011
EU Approves Novartis's laBCC Therapy Novartis has announced that the European Commission has approved Odomzo® 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to curative surgery or radiation therapy. Monday, August 24, 2015Novartis Provides Drug Candidate Compounds to TB Alliance Exclusive worldwide license from Novartis includes a novel class of drugs that is active against drug sensitive and multi-resistant strains of tuberculosis. Wednesday, August 20, 2014Novartis Announces Portfolio Transformation Company launches a major overhaul of its business, unveiling a series of multibillion-dollar deals with GSK and Eli Lilly. Wednesday, April 23, 2014